Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr Reddy’s Laboratories ( (RDY) ) has issued an update.
On July 24, 2025, Dr. Reddy’s Laboratories announced the publication of its unaudited financial results for the quarter ending June 30, 2025. The results were advertised in the Financial Express and Andhra Prabha newspapers, highlighting the company’s ongoing transparency and compliance with regulatory requirements. This announcement underscores Dr. Reddy’s commitment to maintaining investor confidence and adhering to financial disclosure norms.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The overall stock score of 68 reflects strong financial performance and reasonable valuation, offset by bearish technical indicators. The company’s solid balance sheet and consistent revenue growth bolster its financial health, but short-term market momentum suggests caution.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a pharmaceutical company based in Hyderabad, India, known for its production of generic medications, active pharmaceutical ingredients, and biosimilars. The company focuses on providing affordable and innovative medicines to patients worldwide.
Average Trading Volume: 1,580,443
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.2B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.